Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Publication · PubMed Indexing for Generic Drug Research

Choosing PubMed Journals to Publish Generic Drug Papers: Indexing, PMC Deposit and NIH Public Access

For bioequivalence and generic-drug research funded by US federal grants, journal choice depends not only on scope and impact factor but also on whether the venue permits compliance with the NIH public-access deposit requirement.

Pubrica AcademyWritten by a regulatory and pharmaceutical publication strategist Reviewed bya pharmacology and bioequivalence subject-matter reviewer Published10 October 2026 Last checked10 October 2026 Reading time7 minutes Sources10 peer-reviewed

Generic-drug and bioequivalence research occupies an unusual position in publishing, spanning clinical pharmacology, regulatory science and health policy. Because of this breadth, authors often default to a journal in which they have previously published without checking two matters specific to US federally funded work: whether the journal’s indexing extends to PubMed/PMC, and whether its deposit workflow is compatible with the NIH Public Access Policy. Neither is optional once a paper is attributable to NIH funding.

Learning objectives

  • Why PubMed indexing alone does not constitute NIH Public Access compliance
  • The requirements and timing of the current NIH Public Access Policy
  • The influence of bioequivalence-specific debates in the literature on the placement of this research
  • A practical sequence for assessing a candidate journal before submission

Common misconceptions

  • “If a journal is PubMed-indexed, an NIH-funded paper automatically satisfies the public access requirement.” PubMed indexing (search visibility) is a system separate from PubMed Central (PMC) deposit (full-text public access). Under the current NIH Public Access Policy, an NIH-funded author manuscript accepted for publication on or after July 1, 2025 must be deposited in PMC and made available with no embargo; the searchability of a journal on PubMed does not by itself satisfy this requirement.
  • “Generic drug substitution studies constitute a settled, low-controversy area, so journal choice is of little consequence.” The literature on bioequivalence and generic substitution remains actively debated. A 2011 CMAJ commentary describes a persistent “backlash” against bioequivalence standards, particularly for narrow-therapeutic-index drugs, based largely on observational data and case reports rather than well-controlled trials; this is the kind of nuance that rigorous peer review in an appropriately chosen journal should test.

PubMed indexing and PMC deposit as distinct systems

PubMed is the bibliographic search index of the National Institutes of Health (NIH); PubMed Central (PMC) is the NIH full-text digital repository. The National Library of Medicine’s own guidance distinguishes the two explicitly: PubMed indexes citations and abstracts drawn largely from MEDLINE-selected journals, whereas PMC is a separate archive of complete, full-text articles9. A journal can be indexed in PubMed (with its titles, abstracts and metadata searchable) without the full text of every article being deposited in PMC. For most authors this distinction is of limited practical importance. For authors whose generic-drug or bioequivalence research was funded, even in part, by an NIH grant, it is consequential, because the funding agency’s compliance requirement applies specifically to PMC deposit, not to PubMed searchability alone.

Requirements of the NIH Public Access Policy

The current NIH Public Access Policy requires that peer-reviewed articles arising from NIH funding be made publicly available through PMC. Under the 2024 update to the policy, author manuscripts accepted for journal publication on or after July 1, 2025 must be deposited in PMC for immediate public access, with no embargo period, and the article must be publicly available without embargo as of its official publication date 1.

In practice, deposit is therefore due at the point of acceptance, not months later. When a journal is being selected for generic-drug or bioequivalence research associated with NIH funding, authors should confirm early whether the journal has an established direct-deposit pipeline for NIH-funded manuscripts, since responsibility for timely, compliant deposit ultimately rests with the author, not the journal.

The need for careful placement of bioequivalence research

Generic-drug substitution remains a contested area of clinical pharmacology, which is a reason to select a journal with rigorous, subject-matched peer review rather than the first PubMed-indexed outlet willing to accept the paper. A 2011 commentary in CMAJ outlines the debate: generics fill the large majority of prescriptions in many health systems, yet scepticism about regulatory bioequivalence standards persists, particularly for narrow-therapeutic-index drugs such as antiepileptics, anticoagulants, digoxin and amiodarone 2. The author notes that a Food and Drug Administration (FDA) review of approved generics found an average pharmacodynamic difference of only around 4% from the reference product, and argues that much of the published scepticism rests on case reports and underpowered observational studies rather than well-controlled trials 2.

Separately, the clinical pharmacology literature has examined how bioequivalence findings translate into therapeutic equivalence for specific drug classes; for example, work comparing different salt forms of amlodipine has raised the question of whether bioequivalence data alone establish clinical interchangeability for every formulation 3. A journal whose editorial board and reviewer pool are equipped to adjudicate such pharmacokinetic nuance is a more appropriate choice than a generalist outlet that is merely PubMed-indexed.

A practical sequence for journal selection

Taken together, journal selection for generic-drug and bioequivalence papers associated with NIH funding should proceed through three checks, in order: first, whether the journal’s subject scope and editorial board correspond to bioequivalence and pharmacokinetic science rather than generalist health policy; second, whether the journal supports, or at a minimum does not obstruct, timely PMC deposit for NIH-funded manuscripts; and third, whether the journal’s peer-review rigour is appropriate for a clinical question that remains debated, as opposed to a rapid, low-scrutiny venue. Omitting the second check is the most common and most costly error, since non-compliance places future NIH funding at risk, not only the publication itself.

An ongoing example: generic levothyroxine

The scepticism regarding narrow-therapeutic-index drugs described in the Kesselheim commentary is not merely of historical interest; it is currently evident in the literature on levothyroxine, a thyroid hormone replacement that most patients take for life. Generic drugs fill about 90% of all U.S. prescriptions but account for only roughly 20% of prescription drug spending4, yet the generic prescribing rate for levothyroxine is well below that 90% average, in part because the American Thyroid Association has advised against switching between generic levothyroxine products without additional monitoring, specifically questioning whether the FDA’s direct hormone-level bioequivalence standard is appropriate for this drug4. An FDA-sponsored retrospective study of more than 15,000 patients, published in JAMA Internal Medicine in 2022, directly tested this concern and found that patients who switched between different generic levothyroxine products had the same average serum thyrotropin (TSH) levels as patients who remained on a single product5. The FDA’s own interpretation is that this real-world evidence is consistent with its bioequivalence standards and in tension with the more cautious guidance of the professional society4; this is an unresolved disagreement between a regulator and a specialty society, and precisely the kind of nuance that a well-matched, rigorous peer-review venue must be equipped to adjudicate rather than accepting either party’s framing uncritically.

The scale of the market in which a submission competes

This prescribing gap has commercial as well as clinical significance. The Association for Accessible Medicines’ 2023 savings report estimated that generic and biosimilar medicines saved the U.S. healthcare system $408 billion in 2022 alone, with generics and biosimilars together filling over 90% of prescriptions dispensed that year6. A manuscript on generic-drug substitution, bioequivalence or cost policy therefore does not address a niche topic with a small specialist readership; it belongs to one of the largest and most policy-relevant segments of the pharmaceutical literature. This is a further reason to place it with a journal whose editorial board and readership are positioned to engage with regulatory and health-economic nuance, rather than with a generalist outlet that will publish it but cannot referee it meaningfully.

Two FDA resources relevant to bioequivalence authors

Two FDA resources should be consulted before the framing of a generic-drug manuscript is finalized, because reviewers at a well-matched journal will expect familiarity with both. The Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) is the FDA’s authoritative public listing of the generic products formally rated therapeutically equivalent to their reference product, and is the correct primary source for any claim about a specific drug’s equivalence rating, in preference to a manufacturer’s marketing claims7. Separately, the Generic Drug User Fee Amendments (GDUFA) program, periodically reauthorized by Congress, funds and sets performance goals for the FDA’s generic-drug review process; an understanding of the priorities of its current cycle (for example, complex generics or first-generic review timelines) can help authors explain why a given bioequivalence question is of current regulatory relevance rather than purely academic interest8.

Criteria for MEDLINE/PubMed indexing of a journal

An understanding of how a journal obtains MEDLINE indexing explains why the question of whether a journal is PubMed-indexed is a useful screening question rather than a formality. NLM decides whether to index a journal on the basis of its “scientific and editorial character and quality”, weighed against NLM’s collection-development policy and the recommendations of external consultants, typically a scientist and a medical librarian who review a sample of the journal’s recent content directly rather than applying a fixed pass/fail list10. This review considers five elements: the clarity of the journal’s scope and its contribution to biomedicine; the transparency of its editorial policies, including peer review, ethics statements and conflict-of-interest disclosure; the scientific and methodological rigour evident in its published articles, including complete abstracts and reproducible methods; the consistency of its production and administration, from publication schedules to article structure; and its overall impact and significance in its field10. For a bioequivalence or generic-drug manuscript, a journal’s PubMed indexing status therefore serves as a proxy for the editorial rigour that a contested narrow-therapeutic-index debate requires, rather than an administrative requirement separate from the question of quality.

Key points

Key points

PubMed searchability and NIH Public Access compliance are different systems; for NIH-funded generic-drug research, the choice of journal must satisfy the PMC deposit requirement as well as PubMed indexing.

Practical application

Practical application

  1. The two systems should be distinguished. PubMed indexing and PMC deposit should be treated as two distinct checks rather than one.
  2. The deposit timeline should be confirmed. For manuscripts accepted on or after July 1, 2025, PMC deposit with no embargo is required at acceptance.
  3. The journal should be matched to the pharmacological content. A journal whose scope and reviewers are equipped to assess bioequivalence and pharmacokinetic nuance should be selected in preference to a generalist outlet.
  4. Funding should be documented at submission. NIH award numbers should be disclosed at submission so that the publisher’s PMC deposit workflow, where one exists, is triggered correctly.

Frequently asked questions

The NIH requirement is PMC deposit of the peer-reviewed manuscript, not PubMed indexing specifically, although most PMC-deposited articles are also discoverable through PubMed.

Under the current policy, deposit is due upon acceptance, and manuscripts accepted on or after July 1, 2025 must be made publicly available with no embargo as of the official publication date.

Because bioequivalence standards for some drug classes remain actively debated in the published literature, as documented in commentary analysing the evidentiary basis of that scepticism.

References

  1. National Institutes of Health. NIH Public Access Policy. read 10 October 2026. View source
  2. Kesselheim AS. The backlash against bioequivalence and the interchangeability of brand-name and generic drugs. CMAJ. 2011;183(12):1350-1351. read 10 October 2026. View source
  3. Meredith PA. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms. Current Medical Research and Opinion. 2009;25(9):2179-2189. read 10 October 2026. View source
  4. U.S. Food and Drug Administration. Real-World Case Study: Levothyroxine Use Addresses Institutional Concerns About Generic Product Switching. read 10 October 2026. View source
  5. Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults. JAMA Internal Medicine. 2022. read 10 October 2026. View source
  6. Association for Accessible Medicines. 2023 US Generics & Biosimilar Medicines Savings Report. read 10 October 2026. View source
  7. U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). read 10 October 2026. View source
  8. U.S. Food and Drug Administration. Generic Drug User Fee Amendments (GDUFA). read 10 October 2026. View source
  9. PubMed Central. Frequently Asked Questions: difference between MEDLINE, PubMed, and PubMed Central. read 10 October 2026. View source
  10. National Library of Medicine. Journal Selection for MEDLINE: criteria used by the Literature Selection Technical Review Committee. read 10 October 2026. View source

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). Choosing PubMed Journals to Publish Generic Drug Papers: Indexing, PMC Deposit and NIH Public Access. Pubrica. https://pubrica.com/academy/journal-selection/how-to-choose-pubmed-journals-to-publish-generic-drug-papers/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

NIH-compliant journal screen

This checklist should be completed before NIH-funded bioequivalence research is submitted.

[ ] Journal scope matches bioequivalence/pharmacokinetic science
[ ] Journal's PMC deposit pathway confirmed
[ ] NIH award number ready to disclose at submission
[ ] Deposit timeline checked against acceptance date
[ ] Peer-review rigor appropriate for a contested clinical question

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica's publication support team screens candidate journals for both subject fit and NIH Public Access compliance before generic-drug manuscripts are submitted.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Journal selection for NIH-funded generic-drug research

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.